WO2017049328A1 - A chewable gum composition - Google Patents

A chewable gum composition Download PDF

Info

Publication number
WO2017049328A1
WO2017049328A1 PCT/ZA2016/050033 ZA2016050033W WO2017049328A1 WO 2017049328 A1 WO2017049328 A1 WO 2017049328A1 ZA 2016050033 W ZA2016050033 W ZA 2016050033W WO 2017049328 A1 WO2017049328 A1 WO 2017049328A1
Authority
WO
WIPO (PCT)
Prior art keywords
gum composition
chewable gum
plant extract
chewable
glycyrrhiza glabra
Prior art date
Application number
PCT/ZA2016/050033
Other languages
French (fr)
Inventor
Eugene OLIVIER
Damien ALIHANGA
Patrick DEMANA
Original Assignee
Tshwane University Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tshwane University Of Technology filed Critical Tshwane University Of Technology
Publication of WO2017049328A1 publication Critical patent/WO2017049328A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00Chewing gum
    • A23G4/06Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/068Chewing gum characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/48Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537Salvia (sage)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058Chewing gums

Definitions

  • the invention relates to a chewable gum composition.
  • BACKGROUND ART Recurrent Aphtous Stomatitis (RAS), Recurrent Aphtous Ulceration (RAU), canker sores, aphthae or aphtous ulcers is an inflammatory condition of unknown aetiology characterised by painful recurrent, single or multiple ulcerations of the oral mucosa.
  • Canker sores are the most common of all non - traumatic ulcerative and vesicular lesions of the oral cavity (Natah et al., 2004). The exact cause of canker sores remains unkown, hence the difficulty in determining a curative treatment.
  • the current primary option for treating this condition includes oral topical dosage forms such as pastes, gels, mouthwashes, creams and ointments.
  • a downside of these conventional medicines lies in the fact that they are usually easily removed from the site of action due to tongue and saliva movement, and in addition, are difficult to apply when the ulcer is located in the arched opening at the back of the mouth leading to the pharynx (Patel, Liu & Brown, 201 1 ).
  • Another disadvantange is the quick release and sudden termination of active substance availability at the required site of action.
  • a chewable gum composition which includes:- a Salvia officinalis plant extract;
  • a carrier for carrying and releasing the plant extracts when chewing the chewable gum composition.
  • percentage fraction will be understood to mean weight by weight (W/W) percentages.
  • any portion of the leaves and / or roots and / or stems of Salvia officinalis may be used to manufacture the Salvia officinalis based plant extract.
  • the Salvia officinalis plant extract may have an extract factor and / or strength of 5:1 meaning that 5 units of Salvia officinalis plant material is used to produce 1 unit of Salvia officinalis plant extract.
  • the Salvia officinalis plant extract may comprise up to 35 % of the chewable gum composition.
  • the Salvia officinalis plant extract may comprise between 8 mg and 450 mg of the chewable gum composition.
  • the Salvia officinalis plant extract may contain rosmarinic acid and caffeic acid.
  • the Salvia officinalis plant extract may contain about 0.105% rosmarinic acid and 0.0126% caffeic acid when using a 5:1 Salvia officinalis plant extract. Any portion of the leaves and / or roots and / or stems of Glycyrrhiza glabra may be used to manufacture the Glycyrrhiza glabra based plant extract.
  • the Glycyrrhiza glabra plant extract may have an extraction and / or processed factor of 4:1 meaning that 4 units of Glycyrrhiza glabra plant material is used to produce 1 unit of Glycyrrhiza glabra plant extract.
  • the Glycyrrhiza glabra plant extract may comprise up to 20 % of the chewable gum composition.
  • the Glycyrrhiza glabra plant extract may comprise between 4 mg and 250 mg of the chewable gum composition.
  • the Glycyrrhiza glabra plant extract may contain glycyrrhizic acid.
  • the Glycyrrhiza glabra plant extract may contain about 2.383 % glycyrrhizic acid when using a 4:1 Glycyrrhiza glabra plant extraction.
  • the rosmarinic acid may comprise between 0.01 mg and 1 mg of the chewable gum composition.
  • the rosmarinic acid may comprise up to 1 % of the chewable gum composition.
  • the caffeic acid may comprise between 0.01 mg and 1 mg of the chewable gum composition.
  • the caffeic acid may comprise up to 1 % of the chewable gum composition.
  • the glycyrrhizic acid may comprise between 0.1 mg and 6 mg of the chewable gum composition.
  • the glycyrrhizic acid may comprise up to 3 % of the chewable gum composition.
  • the carrier may be in the form of any suitable excipient for allowing the sustained and / or modified release of the plant extracts when chewing the chewable gum composition.
  • the carrier may be in the form of a chewable gum.
  • the carrier may comprise any one or more of the group consisting of a gum base, an elastomer, an emulsifier, a filler, a wax, an antioxidant, a softener, a sweetener, a food colouring and / or flavouring agent.
  • the percentage fraction of carrier : Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract in the chewable gum composition may be in the range of 49 % - 99 % : 0.5 % - 32 % : 0.5 % - 20 %.
  • the percentage fraction of carrier Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract in the chewable gum composition may be about 90% : 6.4 % : 3.6 %
  • the chewable gum composition may further also include any one or more pharmaceutical excipients commonly used for formulating a solid oral dosage form, such as a chewable tablet, selected from the group consisting of a glidant, a lubricant, a binder, a taste masking agent, a flavour absorbing agent and a flavourant.
  • a pharmaceutical excipients commonly used for formulating a solid oral dosage form such as a chewable tablet, selected from the group consisting of a glidant, a lubricant, a binder, a taste masking agent, a flavour absorbing agent and a flavourant.
  • the glidant in turn may be selected from any one or more of the group consisting of talc (magnesium hydrous silicate), and colloidal silicon dioxide.
  • the lubricant may be selected from any one or more of the group consisting of magnesium stearate, stearic acid, sodium stearyl fumerate and sodium behenate.
  • the binder may be selected from any one or more of the group consisting of hydroxypropylcellulose, methylcellulose, hypromellose, polyvinylpyrrolidone (povidone) and copovidone.
  • the taste masking agent may be in the form of citric acid monohydrate.
  • the flavour absorbing agent may be in the form of calcium carbonate.
  • the flavourant may be selected from any one or more of the group consisting of wild cherry and spearmint liquid.
  • the percentage fraction of the carrier Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract : glidant : lubricant : binder : taste masking agent : flavourant absorbing agent : flavourant in the chewable gum composition may be in the range of 40 - 90% : 0.5 - 30 % : 0.5 - 20 % : 1 - 5 % : 0.1 - 3 % : 1 - 10 % : 0,1 - 3 % : 1 - 5 % : 0.1 - 5 %.
  • the percentage fraction of the carrier Salvia officinalis based plant extract :
  • Glycyrrhiza glabra based plant extract glidant : lubricant : binder : taste masking agent : flavourant absorbing agent : flavourant in the chewable gum composition may be 78.27% : 5.55 % : 3.26 % : 2.24 % : 0.25 % : 5 % : 0.3 % : 2.25 % : 2.88 %.
  • the weight ratio of the carrier Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract : glidant : lubricant : binder : taste masking agent : flavourant absorbing agent : flavourant in the chewable gum composition may be 1 173.88 mg : 83.33 mg : 48.93 mg : 33.69 mg : 3.75 mg : 75 mg : 4.5 mg : 33.69 mg : 43.23 mg.
  • the chewable gum composition may be in the form of a solid oral dosage form, such as a conventional chewable tablet.
  • the composition may be film and / or sugar coated to enhance the stability / and or organoleptic properties thereof.
  • the film coating may comprise any commonly used excipient used in the pharma industry for coating tablets, such as hydroxypropyl methylcellulose (HPMC).
  • HPMC hydroxypropyl methylcellulose
  • the film coating may comprise between 1 % and 6 % of the total dosage mass.
  • a chewable gum composition presented preferably in tablet form to a user, for treating oral canker sores.
  • the delivery site having a fairly large contact surface leading to increased quantities of drug being absorbed at a faster rate of absorption.
  • the Applicant considers the invention advantageous in that a chewable gum composition in tablet form is provided for releasing Glycyrrhiza glabra and Salvia officinalis plant extracts and thereby the active ingredients rosmarinic acid, caffeic acid and glycyrrhizic in the oral cavity when chewing the said composition for treating conditions such as oral canker sores.

Abstract

According to the invention there is provided a chewable gum composition, which includes a Salvia officinalis plant extract, a Glycyrrhiza glabra plant extract and a carrier for carrying and releasing the plant extracts when chewing the chewable gum composition.

Description

A CHEWABLE GUM COMPOSITION
TECHNICAL FIELD
The invention relates to a chewable gum composition. BACKGROUND ART Recurrent Aphtous Stomatitis (RAS), Recurrent Aphtous Ulceration (RAU), canker sores, aphthae or aphtous ulcers, is an inflammatory condition of unknown aetiology characterised by painful recurrent, single or multiple ulcerations of the oral mucosa. Canker sores are the most common of all non - traumatic ulcerative and vesicular lesions of the oral cavity (Natah et al., 2004). The exact cause of canker sores remains unkown, hence the difficulty in determining a curative treatment.
Currently available treatments are symptomatic and aimed at reducing pain, the healing period, reducing the number and size of ulcers, and also prevention of recurrence (Scully, Gorsky & Lozada - Nur, 2003).
The current primary option for treating this condition includes oral topical dosage forms such as pastes, gels, mouthwashes, creams and ointments.
A downside of these conventional medicines lies in the fact that they are usually easily removed from the site of action due to tongue and saliva movement, and in addition, are difficult to apply when the ulcer is located in the arched opening at the back of the mouth leading to the pharynx (Patel, Liu & Brown, 201 1 ). Another disadvantange is the quick release and sudden termination of active substance availability at the required site of action.
The inventors having considered the above propose a chewable gum composition as disclosed hereunder.
SUMMARY OF THE INVENTION
According to the invention there is provided a chewable gum composition, which includes:- a Salvia officinalis plant extract;
a Glycyrrhiza glabra plant extract; and
a carrier for carrying and releasing the plant extracts when chewing the chewable gum composition.
In this specification, unless the context dictates otherwise, percentage fraction will be understood to mean weight by weight (W/W) percentages.
Any portion of the leaves and / or roots and / or stems of Salvia officinalis may be used to manufacture the Salvia officinalis based plant extract.
The Salvia officinalis plant extract may have an extract factor and / or strength of 5:1 meaning that 5 units of Salvia officinalis plant material is used to produce 1 unit of Salvia officinalis plant extract.
The Salvia officinalis plant extract may comprise up to 35 % of the chewable gum composition.
The Salvia officinalis plant extract may comprise between 8 mg and 450 mg of the chewable gum composition.
The Salvia officinalis plant extract may contain rosmarinic acid and caffeic acid. The Salvia officinalis plant extract may contain about 0.105% rosmarinic acid and 0.0126% caffeic acid when using a 5:1 Salvia officinalis plant extract. Any portion of the leaves and / or roots and / or stems of Glycyrrhiza glabra may be used to manufacture the Glycyrrhiza glabra based plant extract.
The Glycyrrhiza glabra plant extract may have an extraction and / or processed factor of 4:1 meaning that 4 units of Glycyrrhiza glabra plant material is used to produce 1 unit of Glycyrrhiza glabra plant extract.
The Glycyrrhiza glabra plant extract may comprise up to 20 % of the chewable gum composition.
The Glycyrrhiza glabra plant extract may comprise between 4 mg and 250 mg of the chewable gum composition.
The Glycyrrhiza glabra plant extract may contain glycyrrhizic acid.
The Glycyrrhiza glabra plant extract may contain about 2.383 % glycyrrhizic acid when using a 4:1 Glycyrrhiza glabra plant extraction.
The rosmarinic acid may comprise between 0.01 mg and 1 mg of the chewable gum composition.
The rosmarinic acid may comprise up to 1 % of the chewable gum composition.
The caffeic acid may comprise between 0.01 mg and 1 mg of the chewable gum composition.
The caffeic acid may comprise up to 1 % of the chewable gum composition.
The glycyrrhizic acid may comprise between 0.1 mg and 6 mg of the chewable gum composition.
The glycyrrhizic acid may comprise up to 3 % of the chewable gum composition. The carrier may be in the form of any suitable excipient for allowing the sustained and / or modified release of the plant extracts when chewing the chewable gum composition.
The carrier may be in the form of a chewable gum. The carrier may comprise any one or more of the group consisting of a gum base, an elastomer, an emulsifier, a filler, a wax, an antioxidant, a softener, a sweetener, a food colouring and / or flavouring agent.
The percentage fraction of carrier : Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract in the chewable gum composition may be in the range of 49 % - 99 % : 0.5 % - 32 % : 0.5 % - 20 %.
The percentage fraction of carrier : Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract in the chewable gum composition may be about 90% : 6.4 % : 3.6 %
The chewable gum composition may further also include any one or more pharmaceutical excipients commonly used for formulating a solid oral dosage form, such as a chewable tablet, selected from the group consisting of a glidant, a lubricant, a binder, a taste masking agent, a flavour absorbing agent and a flavourant.
The glidant in turn may be selected from any one or more of the group consisting of talc (magnesium hydrous silicate), and colloidal silicon dioxide. The lubricant may be selected from any one or more of the group consisting of magnesium stearate, stearic acid, sodium stearyl fumerate and sodium behenate.
The binder may be selected from any one or more of the group consisting of hydroxypropylcellulose, methylcellulose, hypromellose, polyvinylpyrrolidone (povidone) and copovidone. The taste masking agent may be in the form of citric acid monohydrate.
The flavour absorbing agent may be in the form of calcium carbonate. The flavourant may be selected from any one or more of the group consisting of wild cherry and spearmint liquid.
The percentage fraction of the carrier : Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract : glidant : lubricant : binder : taste masking agent : flavourant absorbing agent : flavourant in the chewable gum composition may be in the range of 40 - 90% : 0.5 - 30 % : 0.5 - 20 % : 1 - 5 % : 0.1 - 3 % : 1 - 10 % : 0,1 - 3 % : 1 - 5 % : 0.1 - 5 %. The percentage fraction of the carrier : Salvia officinalis based plant extract :
Glycyrrhiza glabra based plant extract : glidant : lubricant : binder : taste masking agent : flavourant absorbing agent : flavourant in the chewable gum composition may be 78.27% : 5.55 % : 3.26 % : 2.24 % : 0.25 % : 5 % : 0.3 % : 2.25 % : 2.88 %. The weight ratio of the carrier : Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract : glidant : lubricant : binder : taste masking agent : flavourant absorbing agent : flavourant in the chewable gum composition may be 1 173.88 mg : 83.33 mg : 48.93 mg : 33.69 mg : 3.75 mg : 75 mg : 4.5 mg : 33.69 mg : 43.23 mg.
The chewable gum composition may be in the form of a solid oral dosage form, such as a conventional chewable tablet. The composition may be film and / or sugar coated to enhance the stability / and or organoleptic properties thereof. The film coating may comprise any commonly used excipient used in the pharma industry for coating tablets, such as hydroxypropyl methylcellulose (HPMC). The film coating may comprise between 1 % and 6 % of the total dosage mass.
DETAILED DESCRIPTION OF THE INVENTION
The invention will now be described according a non - limiting example only. According to the invention there is provided a chewable gum composition presented preferably in tablet form to a user, for treating oral canker sores.
In accordance with a preferred embodiment of the invention the chewable gum composition will be composed according to the formula set out hereunder:
EXAMPLE 1
Ingredient W/W %
Gum base 78.27
Salvia officinalis plant extract 5.55
Glycyrrhiza glabra plant extract 3.26
Talc 2.24
Magnesium stearate 0.25
PVP (K 30) 5.00
Citric acid monohydrate 0.30
Calcium carbonate 2.25
Wilde cherry flavour 1 .00
Spearmint oil flavour 1 .88 EXAMPLE 2
Ingredient W/W %
Gum base 84.58
Rosmarinic acid 0.105
Caffeic acid 0.0126
Glycyrrhizic acid 2.383
Talc 2.24
Magnesium stearate 0.25
PVP (K 30) 5.00
Citric acid monohydrate 0.30
Calcium carbonate 2.25
Wilde cherry flavour 1 .00
Spearmint oil flavour 1 .88
It shall be understood that the examples are provided for illustrating the invention further and to assist a person skilled in the art with understanding the invention and are not meant to be construed as unduly limiting the reasonable scope of the invention.
Advantages of oral cavity drug delivery:
- ease of administration
- rapid onset of action and continuous drug delivery
- avoidance of the harsh conditions within the gastrointestinal tract
- rapid reach of therapeutic concentrations of the drug
- bypass of hepatic first - pass metabolism which decrease drug bioavailability enhances patient compliance due to ease of administration
easy access to delivery site, the delivery site having a fairly large contact surface leading to increased quantities of drug being absorbed at a faster rate of absorption.
The Applicant considers the invention advantageous in that a chewable gum composition in tablet form is provided for releasing Glycyrrhiza glabra and Salvia officinalis plant extracts and thereby the active ingredients rosmarinic acid, caffeic acid and glycyrrhizic in the oral cavity when chewing the said composition for treating conditions such as oral canker sores.

Claims

A chewable gum composition, which includes:- a Salvia officinalis plant extract;
a Glycyrrhiza glabra plant extract; and
a carrier for carrying and releasing the plant extracts when chewing the chewable gum composition.
A chewable gum composition as claimed in claim 1 wherein the Salvia officinalis plant extract has an extraction factor and / or strength of 5:1.
A chewable gum composition as claimed in any one or more of the preceding claims wherein the Salvia officinalis plant extract comprises up to 35 % of the chewable gum composition.
A chewable gum composition as claimed in any one or more of the preceding claims wherein the Salvia officinalis plant extract contains rosmarinic acid and caffeic acid.
A chewable gum composition as claimed in claim 4 wherein the Salvia officinalis plant extract contains about 0.105% rosmarinic acid and 0.0126% caffeic acid.
A chewable gum composition as claimed in any one or more of the preceding claims wherein the rosmarinic acid comprises up to 1% of the said chewable gum composition.
A chewable gum composition as claimed in any one or more of the preceding claims wherein the caffeic acid comprises up to 1 % of the chewable gum composition.
A chewable gum composition as claimed in any one or more of the preceding claims wherein The Glycyrrhiza glabra plant extract has an extraction and / or processed factor of 4:1 .
A chewable gum composition as claimed in any one or more of the preceding claims wherein the Glycyrrhiza glabra plant extract comprises up to 20 % of the chewable gum composition.
A chewable gum composition as claimed in any one or more of the preceding claims wherein the Glycyrrhiza glabra plant extract contains glycyrrhizic acid.
A chewable gum composition as claimed in claim 10 wherein the Glycyrrhiza glabra plant extract contains about 2.383 % glycyrrhizic acid.
A chewable gum composition as claimed in any one or more of the preceding claims wherein the glycyrrhizic acid comprises up to 3 % of the chewable gum composition.
A chewable gum composition as claimed in any one or more of the preceding claims wherein the carrier allows modified release of the Salvia officinalis and Glycyrrhiza glabra plant extracts when chewed.
A chewable gum composition as claimed in any one or more of the preceding claims wherein the carrier allows modified release of rosmarinic acid, caffeic acid and glycyrrhizic acid when chewed.
A chewable gum composition as claimed in any one or more of the preceding claims wherein the carrier comprises of any one or more of the group consisting of a gum base, an elastomer, an emulsifier, a filler, a wax, an antioxidant, a softener, a sweetener, a food colouring and / or flavouring agent.
A chewable gum composition as claimed in claim 15 wherein the carrier is in the form of a chewable gum.
17. A chewable gum composition as claimed in any one or more of the preceding claims wherein the percentage fraction of carrier : Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract in the said chewable gum composition is in the range of 49 % - 99 % : 0.5 % - 32 % : 0.5 % - 20 %.
18. A chewable gum composition as claimed in any one or more of the preceding claims wherein the percentage fraction of carrier : Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract in the chewable gum composition is about 90% : 6.4 % : 3.6 %.
19. A chewable gum composition as claimed in any one or more of the preceding claims which includes pharmaceutical excipients selected from any one or more of the group consisting of a glidant, a lubricant, a binder, a taste masking agent, a flavourant absorbing agent and a flavourant.
20. A chewable gum composition as claimed in claim 19 wherein the glidant is selected from any one or more of the group consisting of talc (magnesium hydrous silicate), and colloidal silicon dioxide.
21. A chewable gum composition as claimed in any one or more of claims 19 and 20 wherein the lubricant is selected from any one or more of the group consisting of magnesium stearate, stearic acid, sodium stearyl fumerate and sodium behenate.
22. A chewable gum composition as claimed in any one or more of claims 19 to 21 wherein the binder is selected from any one or more of the group consisting of hydroxypropylcellulose, methylcellulose, hypromellose, polyvinylpyrrolidone (povidone) and copovidone.
A chewable gum composition as claimed in any one or more of claims 19 to 22 wherein the taste masking agent is in the form of citric acid monohydrate.
24. A chewable gum composition as claimed in any one or more of claims 19 to 23 wherein the flavour absorbing agent is in the form of calcium carbonate.
25. A chewable gum composition as claimed in any one or more of claims 19 to 24 wherein the flavourant is selected from any one or more of the group consisting of wild cherry and spearmint liquid.
26. A chewable gum composition as claimed in any one or more of claims 19 to 25 wherein the percentage fraction of the carrier : Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract : glidant : lubricant : binder : taste masking agent : flavourant absorbing agent : flavourant in the chewable gum composition is in the range of 40 - 90% : 0.5 - 30 % : 0.5 - 20 % : 1 - 5 % : 0.1 -
3 % : 1 - 10 % : 0,1 - 3 % : 1 - 5 % : 0.1 - 5 %.
27. A chewable gum composition as claimed in any one or more of claims 19 to 25 wherein the percentage fraction of the carrier : Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract : glidant : lubricant : binder : taste masking agent : flavourant absorbing agent : flavourant in the chewable gum composition is 78.25% : 5.55 % : 3.26 % : 2.24 % : 0.25 % : 5 % : 0.3 % : 2.25 % : 2.88 %.
28. A chewable gum composition as claimed in any one or more of the preceding claims wherein the chewable gum composition is in the form of a solid oral dosage form.
29. A chewable gum composition as claimed in claim 28 wherein the solid oral dosage form includes a conventional chewable tablet.
30. A chewable gum composition as claimed in claim 29 wherein the tablet is film coated.
31. A chewable gum composition as claimed in any one or more of claims 29 and 30 wherein the film coating comprises between 1 % and 6 % of the total tablet mass.
32. A chewable gum composition as claimed in any one or more of claims 29 to 31 wherein the tablet is sugar coated. A chewable gum composition for the treatment of oral canker sores in humans substantially as described herein.
A use of a Salvia officinalis based plant extract and a Glycyrrhiza glabra based plant extract for the manufacture of a chewable gum composition for the treatment of oral canker sores in humans substantially as described herein.
A use of a chewable gum composition for the treatment of oral canker sores in humans substantially as described herein.
PCT/ZA2016/050033 2015-09-16 2016-09-16 A chewable gum composition WO2017049328A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA201506844 2015-09-16
ZA2015/06844 2015-09-16

Publications (1)

Publication Number Publication Date
WO2017049328A1 true WO2017049328A1 (en) 2017-03-23

Family

ID=57868437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ZA2016/050033 WO2017049328A1 (en) 2015-09-16 2016-09-16 A chewable gum composition

Country Status (1)

Country Link
WO (1) WO2017049328A1 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3923984A (en) * 1974-02-11 1975-12-02 Atha Beatrice Z Shelf stable multi-use composition, preparation and use
NL9300683A (en) * 1993-04-21 1994-11-16 Frans De Boer Liquorice wool
WO2001012144A1 (en) * 1999-08-19 2001-02-22 Optiva Corporation Gums containing antimicrobial agents
US6231896B1 (en) * 2000-09-08 2001-05-15 The Goodyear Tire & Rubber Company Chewing gum base stabilized with carnosic acid
EP1236466A1 (en) * 2001-02-28 2002-09-04 Efrat Biopolymers Ltd. Absorbable solid compositions for topical treatment of oral mucosal disorders
US20080274179A1 (en) * 2007-05-02 2008-11-06 Chantal Bergeron Supercritical CO2 liquorice extract and products made there from
US20080317681A1 (en) * 2003-07-11 2008-12-25 Petros Gebreselassie Compositions containing a stain removing complex, and methods of making and using the same
US20120251462A1 (en) * 2011-04-04 2012-10-04 Cognis Ip Management Gmbh Agent For Smoker Dehabituation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3923984A (en) * 1974-02-11 1975-12-02 Atha Beatrice Z Shelf stable multi-use composition, preparation and use
NL9300683A (en) * 1993-04-21 1994-11-16 Frans De Boer Liquorice wool
WO2001012144A1 (en) * 1999-08-19 2001-02-22 Optiva Corporation Gums containing antimicrobial agents
US6231896B1 (en) * 2000-09-08 2001-05-15 The Goodyear Tire & Rubber Company Chewing gum base stabilized with carnosic acid
EP1236466A1 (en) * 2001-02-28 2002-09-04 Efrat Biopolymers Ltd. Absorbable solid compositions for topical treatment of oral mucosal disorders
US20080317681A1 (en) * 2003-07-11 2008-12-25 Petros Gebreselassie Compositions containing a stain removing complex, and methods of making and using the same
US20080274179A1 (en) * 2007-05-02 2008-11-06 Chantal Bergeron Supercritical CO2 liquorice extract and products made there from
US20120251462A1 (en) * 2011-04-04 2012-10-04 Cognis Ip Management Gmbh Agent For Smoker Dehabituation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"THE CR100 SYSTEM. ÖUSE OF CONTROLLED RELEASE FLAVOURS IN CHEWING GUM", CONFECTIONERY PRODUCTION, SPECIALISED PUBLICATIONS LTD., SURREY, GB, vol. 61, no. 4, 1 April 1995 (1995-04-01), pages 308 - 310, XP000512428, ISSN: 0010-5473 *
C MESSIER ET AL: "Licorice and its potential beneficial effects in common oro-dental diseases", ORAL DISEASES, vol. 18, no. 1, 18 August 2011 (2011-08-18), pages 32 - 39, XP055041720, ISSN: 1354-523X, DOI: 10.1111/j.1601-0825.2011.01842.x *
DONG ET AL: "Activation of rapid signaling pathways and the subsequent transcriptional regulation for the proliferation of breast cancer MCF-7 cells by the treatment with an extract of Glycyrrhiza glabra root", FOOD AND CHEMICAL TOXICOLOGY, PERGAMON, GB, vol. 45, no. 12, 23 October 2007 (2007-10-23), pages 2470 - 2478, XP022310495, ISSN: 0278-6915, DOI: 10.1016/J.FCT.2007.05.031 *
NASSIRI ASL M ET AL: "Review of pharmacological effects of glycyrrhiza sp. and its bioactive compounds", PHYTOTHERAPY RESEARCH, JOHN WILEY & SONS LTD. CHICHESTER, GB, vol. 22, no. 6, 1 June 2008 (2008-06-01), pages 709 - 724, XP002523763, ISSN: 0951-418X, [retrieved on 20080429], DOI: 10.1002/PTR.2362 *
SCULLY; GORSKY; LOZADA, NUR, 2003

Similar Documents

Publication Publication Date Title
EP1236466B1 (en) Solid self-adhesive compositions for topical treatment of oral mucosal disorders
RU2382637C2 (en) Pharmaceutical composition for peroral introduction in form of particles with calculated time of release and quickly decomposing tablets containing said composition
JP6294479B2 (en) Oral dispersible film
RU2450819C2 (en) Herbal compositions for treating oral diseases
US20090263467A1 (en) Combination drug therapy using orally dissolving film or orally disintegrating tablet dosage forms to treat dry mouth ailments
EP3328409B1 (en) Composition for the increase of humoral secretion
WO2019199260A2 (en) Formulations comprising herbal extracts
US20130039981A1 (en) Quick Dissolving, Long Acting Zinc Therapeutic Formulations
JP6098634B2 (en) Fast disintegrating tablets
US20120015021A1 (en) Anti-appetite adhesive compositions
US10335443B2 (en) Orodispersible film
ES2922243T3 (en) Composition to prevent headaches
RU2311176C2 (en) Ambroxol for treating pains in oral cavity and pharynx
JP5284070B2 (en) Oral mucosa patch preparation
EP1463488B1 (en) Pharmaceutical composition comprising skimmed milk powder
JP5032003B2 (en) Analgesic and anti-inflammatory lozenges for oral mucosa
KR20150136540A (en) Lozenge for treating a sore throat, hoarseness, and associated dry cough and for treating inflammatory diseases of the oral cavity and of the pharynx
WO2017049328A1 (en) A chewable gum composition
KR20150048890A (en) Pharmaceutical compositions comprising flurbiprofen
Gupta et al. An overview of mouth dissolving films: Formulation aspects
US7985430B2 (en) Solid mucoadhesive composition
EP2959889A1 (en) Orally disintegrating formulations of loxoprofen
JP2009507850A5 (en)
JP6315741B2 (en) Composition for oral cavity containing NSAIDs or heparins
Menra et al. A REVIEW ON BUCCAL FILM: AN INOVATIVE DOSAGE FORM.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16829391

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16829391

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 16829391

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 16829391

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 31.01.2019)